|
Carl S. Goldfischer M.D. has been a director since 2000. He is a Managing Director of Bay City Capital and serves on its Board of Directors and Executive Committee. Dr. Goldfischer's background includes extensive public and private investment and transaction work as well as clinical trial development knowledge. Prior to joining Bay City Capital Dr. Goldfischer was until mid-2000 Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously Dr. Goldfischer was a Research Analyst with the Reliance Insurance Company helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer currently serves as Chairman of the Board of Syntonix Pharmaceuticals and as a director for Avera Pharmaceuticals BrainCells Inc. EnteroMedics Etex Corporation MAP Pharmaceuticals Metabolex and PTC Therapeutics. Dr. Goldfischer is also a member of the Board of Trustees of Sarah Lawrence College. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine and a BA from Sarah Lawrence College. | 